Key Points
- CEO August Troendle sold 21,966 Medpace shares for approximately $13.7 million, reducing his direct stake by 6.1% to 338,225 shares.
- Medpace reported strong quarterly results, with revenue rising 17.2% year over year to $707.3 million and earnings of $4.25 per share beating analyst expectations.
- Despite recent growth and a UBS upgrade to “neutral,” analyst sentiment remains mixed, with the broader consensus at “Hold” and the stock trading down 4.2% near $598.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 21,966 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares in the company, valued at $211,549,590.75. The trade was a 6.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Medpace Trading Down 4.2%
Shares of Medpace stock opened at $598.08 on Friday. The firm has a market cap of $16.69 billion, a P/E ratio of 35.06, a P/E/G ratio of 2.78 and a beta of 1.18. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock's fifty day moving average price is $599.99 and its 200-day moving average price is $520.63.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the firm earned $3.10 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Trending Headlines about Medpace
Here are the key news stories impacting Medpace this week:
- Positive Sentiment: UBS upgraded Medpace from “sell” to “neutral” (effectively “hold”) and raised its price target to $673 from $405. The revised target remains above the recent trading level, suggesting UBS sees less downside risk than previously expected. UBS upgrades Medpace and raises price target
- Positive Sentiment: Medpace’s latest reported quarter showed solid momentum, with revenue increasing 17.2% year over year to $707.3 million and adjusted earnings of $4.25 per share exceeding analyst expectations. Management’s fiscal 2026 earnings guidance remains supportive of the long-term growth narrative. Medpace reports 17.2 percent revenue growth
- Neutral Sentiment: Analyst sentiment remains mixed. Several firms have “hold” ratings, while others maintain bullish views; the broader consensus is near a hold rating, indicating that expectations for Medpace’s strong growth are already reflected in its relatively high valuation.
- Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, following the sale of 26,701 shares worth about $16.6 million one day earlier. The combined sales totaled roughly $30.3 million and reduced his direct ownership by about 13% across the two transactions. Additional smaller reported sales add to concerns about insider confidence, even though Troendle still owns a substantial stake. Medpace CEO stock sale SEC filing
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on MEDP shares. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen upped their target price on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Medpace in a research report on Monday, September 14th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Finally, Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $602.27.
Get Our Latest Report on MEDP
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Johnson Financial Group Inc. purchased a new stake in Medpace during the second quarter valued at approximately $27,000. Jones Financial Companies Lllp acquired a new stake in Medpace in the second quarter valued at approximately $30,000. Allied Private Wealth LLC purchased a new position in Medpace in the second quarter worth $31,000. Kilter Group LLC acquired a new position in shares of Medpace during the second quarter worth $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Medpace during the 2nd quarter valued at $34,000. Hedge funds and other institutional investors own 77.98% of the company's stock.
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
